Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALNY
stocks logo

ALNY

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
627.14M
-4.95%
--
--
723.75M
+44.48%
--
--
933.83M
+57.43%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Alnylam Pharmaceuticals, Inc. (ALNY) for FY2025, with the revenue forecasts being adjusted by 0.98% over the past three months. During the same period, the stock price has changed by 21.97%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.98%
In Past 3 Month
Stock Price
Go Up
up Image
+21.97%
In Past 3 Month
23 Analyst Rating
up Image0
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 328.41 USD with a low forecast of 245.00 USD and a high forecast of 500.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Buy
4 Hold
0 Sell
Strong Buy
up Image0
Current: 308.710
sliders
Low
245.00
Averages
328.41
High
500.00
up Image0
Current: 308.710
sliders
Low
245.00
Averages
328.41
High
500.00
JPMorgan
NULL -> Overweight
maintain
$330 -> $338
2025-06-12
Reason
JPMorgan
Price Target
$330 -> $338
2025-06-12
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Alnylam to $338 from $330 and keeps an Overweight rating on the shares. The firm updated the company's model to reflect higher Amvuttra estimates.
Morgan Stanley
Michael Ulz
Hold
Maintains
$284 → $268
2025-04-11
Reason
Morgan Stanley
Michael Ulz
Price Target
$284 → $268
2025-04-11
Maintains
Hold
Reason
Morgan Stanley lowered the firm's price target on Alnylam to $268 from $284 and keeps an Equal Weight rating on the shares. The firm is slightly below consensus on Q1 TTR franchise sales, but expects a focus on early launch dynamics for Amvuttra in ATTR-CM, the analyst tells investors in a preview heading into earnings for commercial small-to-mid cap biotechnology companies the analyst covers.
Needham
Joseph Stringer
Strong Buy
Reiterates
$320
2025-04-09
Reason
Needham
Joseph Stringer
Price Target
$320
2025-04-09
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$500
2025-04-02
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$500
2025-04-02
Reiterates
Strong Buy
Reason
Scotiabank
Greg Harrison
Buy
Maintains
$338 → $342
2025-03-31
Reason
Scotiabank
Greg Harrison
Price Target
$338 → $342
2025-03-31
Maintains
Buy
Reason
Scotiabank raised the firm's price target on Alnylam to $338 from $300 and keeps an Outperform rating on the shares. The firm expects Amvuttra, the first transthyretin silencer to enter the market for the treatment of transthyretin amyloid cardiomyopathy, to see impressive uptake among the first-line setting given its unique mechanism of action, the analyst tells investors. The drug's launch, however, will likely not gain momentum until 2H of 2025, the firm adds.
Redburn Atlantic
Joshua Smith
Strong Buy
Initiates
$353
2025-03-31
Reason
Redburn Atlantic
Joshua Smith
Price Target
$353
2025-03-31
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY.O) is -286.55, compared to its 5-year average forward P/E of -49.63. For a more detailed relative valuation and DCF analysis to assess Alnylam Pharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-49.63
Current PE
-286.55
Overvalued PE
-3.55
Undervalued PE
-95.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7418.39
Current EV/EBITDA
162.90
Overvalued EV/EBITDA
51022.31
Undervalued EV/EBITDA
-65859.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
16.90
Current PS
12.08
Overvalued PS
21.88
Undervalued PS
11.93

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

ALNY News & Events

Events Timeline

(ET)
2025-06-09
06:01:46
Alnylam receives European Commission approval of AMVUTTRA
select
2025-05-12 (ET)
2025-05-12
07:09:37
Alnylam to present data on HELIOS-B Phase 3 study of vutrisiran
select
2025-04-28 (ET)
2025-04-28
08:06:57
Alnylam announces CHMP opinion recommending approval for vutrisiran
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
06-17MarketWatch
Incyte Corp. stock outperforms competitors on strong trading day

  • Incyte Corp. Stock Performance: Incyte Corp. shares increased by 5.12% to $71.22 during a positive trading session, with the S&P 500 and Dow Jones also rising.

  • Current Stock Status: The company's stock is currently 15.16% below its 52-week high of $83.95 reached on November 8th.

Preview
4.0
06-12Benzinga
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $338

  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and real-time intelligence to help traders succeed in the stock market.

  • Exclusive Community Access: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Preview
5.0
06-11Newsfilter
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

  • Appointment of Dr. John Maraganore: Instil Bio, Inc. has appointed Dr. John Maraganore to the Board of Directors of its subsidiary Axion Bio, focusing on the development of AXN-2510, a bispecific antibody for treating solid tumors, particularly non-small cell lung cancer (NSCLC).

  • Strategic Development of AXN-2510: Dr. Maraganore emphasizes the strong scientific rationale and promising early results of AXN-2510, as the company approaches the completion of enrollment in a Phase 2 trial, aiming to redefine treatment standards for patients with solid tumors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY) stock price today?

The current price of ALNY is 308.71 USD — it has decreased -0.02 % in the last trading day.

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY)'s business?

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

arrow icon

What is the price predicton of ALNY Stock?

Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 328.41 USD with a low forecast of 245.00 USD and a high forecast of 500.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY)'s revenue for the last quarter?

Alnylam Pharmaceuticals Inc revenue for the last quarter amounts to 594.19M USD, increased 20.20 % YoY.

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY)'s earnings per share (EPS) for the last quarter?

Alnylam Pharmaceuticals Inc. EPS for the last quarter amounts to -0.44 USD, decreased -15.38 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alnylam Pharmaceuticals Inc (ALNY)'s fundamentals?

The market is revising Upward the revenue expectations for Alnylam Pharmaceuticals, Inc. (ALNY) for FY2025, with the revenue forecasts being adjusted by 0.98% over the past three months. During the same period, the stock price has changed by 21.97%.
arrow icon

How many employees does Alnylam Pharmaceuticals Inc (ALNY). have?

Alnylam Pharmaceuticals Inc (ALNY) has 2230 emplpoyees as of June 18 2025.

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY) market cap?

Today ALNY has the market capitalization of 40.25B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free